Novavax, Inc. (NASDAQ:NVAX) CFO John Trizzino Sells 5,578 Shares of Stock

Novavax, Inc. (NASDAQ:NVAX) CFO John Trizzino sold 5,578 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $5.72, for a total value of $31,906.16. Following the transaction, the chief financial officer now directly owns 4,800 shares in the company, valued at approximately $27,456. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Novavax stock opened at $5.70 on Friday. Novavax, Inc. has a 12 month low of $4.01 and a 12 month high of $51.60. The stock’s 50 day moving average is $5.41 and its 200-day moving average is $3.68. The company has a market capitalization of $128.70 million, a price-to-earnings ratio of -0.57 and a beta of 2.04.

Novavax (NASDAQ:NVAX) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.61) by ($0.08). The firm had revenue of $3.36 million during the quarter, compared to the consensus estimate of $3.53 million. During the same quarter last year, the firm earned ($2.40) earnings per share. Sell-side analysts predict that Novavax, Inc. will post -5.74 EPS for the current year.

A number of brokerages have weighed in on NVAX. Oppenheimer lowered their price target on Novavax from $25.00 to $13.00 and set an “outperform” rating on the stock in a research report on Tuesday. Zacks Investment Research downgraded Novavax from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. ValuEngine raised Novavax from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, HC Wainwright upped their target price on Novavax from $10.00 to $17.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the company. Novavax presently has a consensus rating of “Hold” and an average target price of $39.40.

Several institutional investors have recently bought and sold shares of NVAX. Edmond DE Rothschild Holding S.A. boosted its stake in shares of Novavax by 86.7% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 1,537,130 shares of the biopharmaceutical company’s stock valued at $847,000 after buying an additional 713,752 shares during the period. SG Americas Securities LLC boosted its stake in shares of Novavax by 3,799.2% in the first quarter. SG Americas Securities LLC now owns 435,107 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 423,948 shares during the period. DekaBank Deutsche Girozentrale boosted its stake in shares of Novavax by 21.8% in the first quarter. DekaBank Deutsche Girozentrale now owns 123,100 shares of the biopharmaceutical company’s stock valued at $185,000 after buying an additional 22,000 shares during the period. Ontario Teachers Pension Plan Board bought a new stake in shares of Novavax in the second quarter valued at approximately $510,000. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of Novavax by 7,685.2% in the first quarter. BNP Paribas Arbitrage SA now owns 79,331 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 78,312 shares during the period. 28.20% of the stock is currently owned by institutional investors.

Novavax Company Profile

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Further Reading: What Factors Can Affect Return on Equity?

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.